Crohn's DiseaseNCT06023030
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
An observational study of Crohn's Disease, run by AbbVie at 104 sites in Japan.
Trial summary
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world. Adverse events and change in disease activity will be assessed. Read more about this study
- Who is it for?
- Ages 15 years and older
- Conditions the study is for
- Crohn's Disease
- How many people
- 240 participants
- Where
- 104 sitesJapan
- Study dates
- 28 Jul 2023to May 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Children and Adult participants with Crohn's disease (CD) in Japan.
Who may be able to join
- Diagnosed with moderately to severely active Crohn's disease (CD).
- Has been prescribed upadacitinib for CD as per most current local approved label after its approval for CD in Japan.
- Within 14 days from the commencement of upadacitinib induction treatment for CD at the participating institution.
Who cannot join
- Currently participating in another interventional clinical research.
- Participants for whom upadacitinib is contraindicated.
- Has been treated with upadacitinib for CD before and continue treatment with upadacitinib for CD at the participation to this study.
Trial locations and contacts
104 sites in 1 country. Contact the study team or a site near you to ask about taking part.
104 sites in 1 country
Japan104 sites, 104 recruiting
- Recruiting
Ohmori Toshihide Gastrointestinal Clinic /ID# 276192
Ageo, Saitama, 362-0075
- Recruiting
Ako-City Hospital /ID# 271276
Ako, Hyōgo, 678-0232
- Recruiting
Anjou Kousei Hospital /ID# 261872
Anjo-shi, Aichi-ken, 446-8602
- Recruiting
Juntendo University Hospital /ID# 265452
Bunkyo-ku, Tokyo, 113-8431
- Recruiting
Fukuoka University Chikushi Hospital /ID# 262686
Chikushino-shi, Fukuoka, 818-8502
- Recruiting
Ginza Central Clinic /ID# 261881
Chuo-ku, Tokyo, 104-0061
- Recruiting
Fukuiken Saiseikai Hospital /ID# 274835
Fukui, 918-8235
- Recruiting
Sakemi clinic /ID# 275589
Fukuoka, Fukuoka, 813-0003
- Recruiting
Fukushima Red Cross Hospital /ID# 275322
Fukushima, 960-8530
- Recruiting
National Hospital Organization Fukuyama Medical Center /ID# 261873
Fukuyama-shi, Hiroshima, 720-8520
- Recruiting
Gifu University Hospital /ID# 266711
Gifu, Gifu, 501-1194
- Recruiting
University of the Ryukyus Hospital /ID# 264430
Ginowan-shi, Okinawa, 901-2725
- Recruiting
Hachinohe City Hospital /ID# 264183
Hachinohe, Aomori, 031-0011
- Recruiting
Kato Clinic /ID# 262650
Hamamatsu, Shizuoka, 432-8061
- Recruiting
Handa City Hospital /ID# 270446
Handa, Aichi-ken, 475-8599
- Recruiting
JA Hiroshima General Hospital /ID# 264432
Hatsukaichi, Hiroshima, 738-8503
- Recruiting
Himeji Chuo Hospital /ID# 272714
Himeji, Hyōgo, 672-8501
- Recruiting
Japanease Red Cross Society Himeji Hospital /ID# 275590
Himeji, 670-8540
- Recruiting
Hyogo Prefectural Harima-Himeji General Medical Center /ID# 274528
Himeji-shi, Hyōgo, 670-0836
- Recruiting
Kaisei Clinic /ID# 261883
Hiroshima, Hiroshima, 730-0017
- Recruiting
Seshimo Gastroy & Procto Clinic /ID# 271658
Ibaraki-shi, Osaka, 567-0882
- Recruiting
Tokai University Hospital /ID# 270949
Isehara, Kanagawa, 259-1193
- Recruiting
Itami City Hospital /ID# 276258
Itami, Hyōgo, 664-8540
- Recruiting
Kagoshima IBD Gastroenterology Clinic /ID# 265505
Kagoshima, Kagoshima-ken, 892-0843
- Recruiting
Sakura Clinic /ID# 268344
Kakamigahara-shi, Gifu, 504-0907
- Recruiting
Gokeikai Ofuna Chuo Hospital /ID# 262649
Kamakura-shi, Kanagawa, 247-0056
- Recruiting
National Hospital Organization Kanazawa Medical Center /ID# 268820
Kanazawa, Ishikawa-ken, 920-8650
- Recruiting
Tsujinaka Hospital - Kashiwanoha /ID# 262648
Kashiwa-shi, Chiba, 277-0871
- Recruiting
Saitama Medical Center /ID# 270948
Kawagoe, Saitama, 350-8550
- Recruiting
Tobata Kyoritsu Hospital /ID# 273558
Kitakyushu, Fukuoka, 804-0093
- Recruiting
Steel Memorial Yahata Hospital /ID# 272713
Kitakyushu, Fukuoka, 805-0050
- Recruiting
Kitakyushu Municipal Medical Center /ID# 276257
Kitakyushu-shi, Fukuoka, 802-0077
- Recruiting
Aoyama Clinic /ID# 262658
Kobe, Hyōgo, 650-0015
- Recruiting
Kobe City Medical Center General Hospital /ID# 270950
Kobe, Hyōgo, 650-0047
- Recruiting
Chikamori Hospital /ID# 267382
Kochi, Kochi, 780-8522
- Recruiting
Kuniyoshi Hospital /ID# 271878
Kochi, 780-0901
- Recruiting
Yamanashi Prefectural Central Hospital /ID# 274526
Kofu, Yamanashi, 400-0027
- Recruiting
Koganei Tsurukame Clinic /ID# 271660
Koganei-shi, Tokyo, 184-0004
- Recruiting
Southern Tohoku General Hospital /ID# 270447
Kōriyama, Fukushima, 963-8563
- Recruiting
Coloproctology Center Takano Hospital /ID# 268868
Kumamoto, Kumamoto, 862-0971
- Recruiting
Hidaka Colon Proctology Clinic /ID# 268867
Kurume, Fukuoka, 839-0809
- Recruiting
Hakuai Clinic /ID# 261876
Kurume-shi, Fukuoka, 839-0863
- Recruiting
Japanese Red Cross Kyoto Daiichi Hosital /ID# 262660
Kyoto, Kyoto, 605-0981
- Recruiting
National Hospital Organization Kyoto Medical Center /ID# 265461
Kyoto, Kyoto, 612-8555
- Recruiting
Matsuyama Red Cross Hospital /ID# 266717
Matsuyama, Ehime, 790-8524
- Recruiting
Dokkyo Medical University Hospital /ID# 266710
Mibu, Tochigi, 321-0293
- Recruiting
Kitasato University Kitasato Institute Hospital /ID# 268345
Minato-ku, Tokyo, 108-8642
- Recruiting
Moriguchi Keijinkai Hospital /ID# 268821
Moriguchi, Osaka, 570-0013
- Recruiting
Aichi Medical University Hospital /ID# 261871
Nagakute, Aichi-ken, 480-1195
- Recruiting
Nagano Municipal Hospital /ID# 262627
Nagano, Nagano, 3818551
- Recruiting
Honda Internal Medicine and Endoscopy Clinic /ID# 275628
Nagasaki, Nagasaki, 850-0058
- Recruiting
Masuko Memorial Hospital /ID# 267420
Nagoya, Aichi-ken, 453-0016
- Recruiting
Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital /ID# 276219
Nagoya, Aichi-ken, 453-8511
- Recruiting
Nagoya City University Hospital /ID# 275588
Nagoya, Aichi-ken, 467-8602
- Recruiting
Naha City Hospital /ID# 261875
Naha, Okinawa, 902-0061
- Recruiting
Hyogo Medical University Hospital /ID# 267383
Nishinomiya-shi, Hyōgo, 663-8501
- Recruiting
Shimizuogimachi Clinic /ID# 276278
Odawara-shi, Kanagawa, 250-0001
- Recruiting
Ishida Clinic of IBD and Gastroenterology /ID# 261884
Ōita, Oita Prefecture, 870-0823
- Recruiting
Ashiya Central Hospital /ID# 275324
Onga-gun, Fukuoka, 807-0101
- Recruiting
Kita-Harima Medical Center /ID# 276256
Ono, Hyōgo, 675-1327
- Recruiting
Kinshukai Infusion Clinic /ID# 261332
Osaka, Osaka, 530-0011
- Recruiting
National Hospital Organization Osaka National Hospital /ID# 264230
Osaka, Osaka, 540-0006
- Recruiting
Osaka Metropolitan University Hospital /ID# 273559
Osaka, Osaka, 545-8586
- Recruiting
Tane General Hospital /ID# 268871
Osaka, Osaka, 550-0025
- Recruiting
Saga-Ken Medical Centre Koseikan /ID# 274957
Saga, 840-8571
- Recruiting
Kitasato University Hospital /ID# 276524
Sagamihara-shi, Kanagawa, 252-0375
- Recruiting
Saitama City Hospital /ID# 266716
Saitama, 336-8522
- Recruiting
Tokitokai Tokito clinic /ID# 262661
Saitama-shi, Saitama, 336-0963
- Recruiting
Osaka Rosai Hospital /ID# 267379
Sakai, Osaka, 591-8025
- Recruiting
Sapporo Ibd Clinic /ID# 281896
Sapporo, Hokkaido, 064-0919
- Recruiting
Sapporo Kosei General Hospital /ID# 267374
Sapporo, 060-0033
- Recruiting
Ohori IBD Clinic /ID# 261882
Setagaya-ku, Tokyo, 155-0032
- Recruiting
Shinjuku Tsurukame Clinic /ID# 276485
Shibuya-ku, Tokyo, 151-0053
- Recruiting
Tokyo Medical University Hospital /ID# 262683
Shinjuku-ku, Tokyo, 160-0023
- Recruiting
Tokyo Women's Medical University Hospital /ID# 274527
Shinjuku-ku, Tokyo, 162-8666
- Recruiting
Shizuoka Aoi Clinic /ID# 267376
Shizuoka, Shizuoka, 420-0881
- Recruiting
Saigusa Clinic Of Coloproctolo /ID# 275627
Sizuoka-shi, Shizuoka, 420-0859
- Recruiting
Fraternity Memorial Hospital /ID# 274976
Sumida-ku, Tokyo, 130-8587
- Recruiting
NHO Shizuoka Medical Center /ID# 275551
Sunto-gun, Shizuoka, 411-8611
- Recruiting
Takamatsu Red Cross Hospital /ID# 268823
Takamatsu, Kagawa-ken, 760-0017
- Recruiting
Maeda Hospital /ID# 275554
Takamatsu, Kagawa-ken, 761-8054
- Recruiting
Fujita Gastroenterology Hospital /ID# 275410
Takatsuki, Osaka, 569-0086
- Recruiting
Tokorozawa Proctogic Hospital /ID# 268870
Tokorozawa, Saitama, 359-1141
- Recruiting
Tokyo Yamate Medical Center /ID# 275591
Tokyo, 169-0073
- Recruiting
Teikyo University Hospital /ID# 274525
Tokyo, 173-8605
- Recruiting
Teikyo University Hospital /ID# 274977
Tokyo, 173-8605
- Recruiting
Yokota Memorial Hospital /ID# 266714
Toyama, Toyama, 939-8085
- Recruiting
Toyohashi Municipal Hospital /ID# 274975
Toyohashi, Aichi-ken, 441-8570
- Recruiting
Municipal Toyonaka Hospital /ID# 266712
Toyonaka, 560-0055
- Recruiting
Ieda Hospital /ID# 259754
Toyota-shi, Aichi-ken, 470-1219
- Recruiting
Mie University Hospital /ID# 262656
Tsu, Mie-ken, 514-8507
- Recruiting
Tsukuba Endoscopy clinic /ID# 261880
Tsukuba, Ibaraki, 305-0821
- Recruiting
Sentohill Hospital /ID# 268869
Ube, Yamaguchi, 755-0155
- Recruiting
Saiseikai Utsunomiya Hospital /ID# 261878
Utsunomiya, Tochigi, 321-0974
- Recruiting
Uwajima City Hospital /ID# 273444
Uwajima, Ehime, 798-0061
- Recruiting
Japanese Red Cross Wakayama Medical Center /ID# 268822
Wakayama, Wakayama, 640-8558
- Recruiting
Wakayama Medical University Hospital /ID# 262685
Wakayama, Wakayama, 641-8510
- Recruiting
Yamagata Prefectural Central Hospital - Yamagata /ID# 268819
Yamagata, 990-2292
- Recruiting
Yamaguchi Red Cross Hospital /ID# 267381
Yamaguchi, 753-8519
- Recruiting
Yokkaichi Hazu Medical Center /ID# 260140
Yokkaichi-shi, Mie-ken, 510-0016
- Recruiting
Matsushima Hospital /ID# 276486
Yokohama, Kanagawa, 220-0041
- Recruiting
Yokohama Municipal Citizen's Hospital /ID# 267375
Yokohama, Kanagawa, 221-0855
- Recruiting
Inoue Gastroenterology Clinic /ID# 275555
Yokohama, Kanagawa, 223-0053
- Recruiting
Saiseikai Yokohama Tobu Hospital /ID# 264186
Yokohama, Kanagawa, 230-0012
About this study
Official title: A Post-marketing Non-interventional Study for Upadacitinib in Patients With Moderately to Severely Active Crohn's Disease (CD) in Japan
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world. Adverse events and change in disease activity will be assessed.
Upadacitinib is a drug approved for the treatment of CD. All study participants will receive upadacitinib as prescribed by their study doctor in accordance with approved local label. Approximately 240 participants will be enrolled in Japan.
Read more
Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 64 weeks.
There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.
- Conditions
- Crohn's Disease
- Keywords
- Crohn's disease, Upadacitinib
- Medical subject headings
- Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Upadacitinib | Participants will receive upadacitinib as prescribed by their physician according to local label. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants with Drug Related Serious Infections
Pecentage of participants with serious infections.
Measured: Up to 64 Weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Sep 2023
- Study start28 Jul 2023
- Primary completionNov 2026 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Crohn's DiseaseStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 240 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06023030
- Sponsor's protocol ID
- P24-080
- Status last verified
- Feb 2026
- First submitted
- 29 Aug 2023
- Last updated
- 24 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Post-marketing Non-interventional Study for Upadacitinib in Patients With Moderately to Severely Active Crohn's Disease (CD) in Japan
- ClinicalTrials.gov ID
- NCT06023030
- Acronym / sponsor ID
- P24-080
- Conditions
- Crohn's Disease
- Keywords
- Crohn's disease, Upadacitinib
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 240 participants (estimated)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 28 Jul 2023 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 5 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world. Adverse events and change in disease activity will be assessed.
Upadacitinib is a drug approved for the treatment of CD. All study participants will receive upadacitinib as prescribed by their study doctor in accordance with approved local label. Approximately 240 participants will be enrolled in Japan.
Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 64 weeks.
There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Upadacitinib | – | –Participants will receive upadacitinib as prescribed by their physician according to local label. |
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Children and Adult participants with Crohn's disease (CD) in Japan.
Key inclusion criteria (3 listed)
- Diagnosed with moderately to severely active Crohn's disease (CD).
- Has been prescribed upadacitinib for CD as per most current local approved label after its approval for CD in Japan.
- Within 14 days from the commencement of upadacitinib induction treatment for CD at the participating institution.
Key exclusion criteria (3 listed)
- Currently participating in another interventional clinical research.
- Participants for whom upadacitinib is contraindicated.
- Has been treated with upadacitinib for CD before and continue treatment with upadacitinib for CD at the participation to this study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of Participants with Drug Related Serious Infections
Time frame: Up to 64 Weeks
Pecentage of participants with serious infections.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Crohn's Disease
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
ABBVIE INC. study director
AbbVie
104 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Crohn's Disease, run by AbbVie at 104 sites in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 104 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact AbbVie GK Clinical Trial Registration Desk (+81-3-4577-1111, abbvie_jpn_info_clingov@abbvie.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants with Drug Related Serious Infections (time frame: Up to 64 Weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2026.